Staying in the Flow: Preferential PDE4B Inhibitor Nerandomilast (BI 1015550) Improves Features of Vascular Dysfunction in Lung Fibrosis In Vitro and In Vivo

被引：0
|
作者：
Reininger, D. [1 ]
Wolf, F. [1 ]
Mayr, C. H. [1 ]
Nickolaus, P. [1 ]
Herrmann, F. E. [1 ]
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Resp Dis Res, Biberach, Germany
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3224
引用
收藏
页数：1
相关论文
共 13 条
  • [1] Development of a Scalable Asymmetric Process for the Synthesis of Selective PDE4B Inhibitor Nerandomilast (BI 1015550)
    Frutos, Rogelio P.
    Tampone, Thomas G.
    Gerstmann, Frank
    Weber, Dirk
    Brodmann, Tobias
    Hagenko''tter, Robert
    Abella, Jocelyn
    Yang, Bing-Shiou
    Mulder, Jason
    Rodriguez, Sonia
    Lee, Heewon
    Gao, Joe
    Song, Jinhua J.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2024, 28 (09) : 3745 - 3751
  • [2] Effect of BI 1015550, a preferential PDE4B inhibitor, on gene expression profiles and lung function in IPF
    Richeldi, Luca
    Roy, Janine
    Schmid, Ramona
    Hesslinger, Christian
    Maher, Toby M.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [3] Effect of BI 1015550, a preferential PDE4B inhibitor, on FEV1/FVC ratio in IPF
    Koschel, D.
    Cottin, V
    Azuma, A.
    Maher, T.
    Valenzuela, C.
    Wijsenbeek, M.
    Liu, Y.
    Stowasser, S.
    Zoz, D.
    Richeldi, L.
    PNEUMOLOGIE, 2024, 78 : S82 - S82
  • [4] Effect of BI 1015550, a preferential PDE4B inhibitor, on FEV1/FVC ratio in IPF
    Cottin, Vincent
    Azuma, Arata
    Maher, Toby M.
    Valenzuela, Claudia
    Wijsenbeek, Marlies S.
    Liu, Yi
    Stowasser, Susanne
    Zoz, Donald F.
    Richeldi, Luca
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [5] BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)
    Sgalla, Giacomo
    Simonetti, Jacopo
    Cortese, Stefania
    Richeldi, Luca
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (01) : 17 - 23
  • [6] Baseline Characteristics of Patients Enrolled in FIBRONEER™-IPF, A Phase III Randomized Placebo-controlled Trial of the Preferential PDE4B Inhibitor Nerandomilast (BI 1015550) in Patients With Idiopathic Pulmonary Fibrosis
    Richeldi, L.
    Assassi, S.
    Azuma, A.
    Cottin, V.
    Hoffmann-Vold, A. M.
    Kreuter, M.
    Liu, Y.
    Maher, T. M.
    Oldham, J. M.
    Stowasser, S.
    Valenzuela, C.
    Wijsenbeek, M. S.
    Zoz, D. F.
    Martinez, F. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [7] BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis
    Herrmann, Franziska Elena
    Hesslinger, Christian
    Wollin, Lutz
    Nickolaus, Peter
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] Effects of nerandomilast, a preferential PDE4B inhibitor, on metabolism of midazolam, a sensitive CYP3A substrate
    Madari, Shilpa
    Yu, Yichao
    Jappar, Dilara
    Zoz, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [9] PDE4B inhibitor BI1015550 improves lung fibrosis, modulates transcriptome in bleomycin-treated rats, and attenuates fibrotic markers in human lung fibroblasts and epithelial cells
    Reininger, Dennis
    Herrmann, Franziska Elena
    Nickolaus, Peter
    Wollin, Lutz
    Laemmle, Baerbel
    Quast, Karsten
    Fundel-Clemens, Katrin
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [10] BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis (vol 13, 838449, 2022)
    Herrmann, Franziska Elena
    Hesslinger, Christian
    Wollin, Lutz
    Nickolaus, Peter
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12